Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Scott David Solomon, M.D.

Co-Author

This page shows the publications co-authored by Scott Solomon and Akshay Desai.
Connection Strength

17.901
  1. Acute Heart Failure: One Syndrome or Many? J Am Coll Cardiol. 2017 06 27; 69(25):3040-3041.
    View in: PubMed
    Score: 0.735
  2. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.
    View in: PubMed
    Score: 0.711
  3. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 07; 36(30):1990-7.
    View in: PubMed
    Score: 0.636
  4. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circ Heart Fail. 2014 Nov; 7(6):895-902.
    View in: PubMed
    Score: 0.610
  5. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
    View in: PubMed
    Score: 0.242
  6. Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. Eur J Heart Fail. 2021 Jun 11.
    View in: PubMed
    Score: 0.242
  7. Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. Circulation. 2021 Jun 08; 143(23):2316-2318.
    View in: PubMed
    Score: 0.242
  8. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2021 05; 9(5):374-382.
    View in: PubMed
    Score: 0.239
  9. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
    View in: PubMed
    Score: 0.238
  10. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 03 09; 77(9):1211-1221.
    View in: PubMed
    Score: 0.237
  11. Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. Eur J Heart Fail. 2021 08; 23(8):1346-1356.
    View in: PubMed
    Score: 0.237
  12. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC Heart Fail. 2021 01; 9(1):13-24.
    View in: PubMed
    Score: 0.232
  13. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020 11; 22(11):2093-2101.
    View in: PubMed
    Score: 0.230
  14. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020 10; 8(10):844-855.
    View in: PubMed
    Score: 0.229
  15. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. JACC Heart Fail. 2020 10; 8(10):811-818.
    View in: PubMed
    Score: 0.227
  16. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC Heart Fail. 2020 08; 8(8):618-626.
    View in: PubMed
    Score: 0.224
  17. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. Circ Heart Fail. 2020 01; 13(1):e006638.
    View in: PubMed
    Score: 0.219
  18. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 02 04; 141(5):352-361.
    View in: PubMed
    Score: 0.217
  19. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020 01 28; 75(3):245-254.
    View in: PubMed
    Score: 0.217
  20. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019 Sep 17; 322(11):1077-1084.
    View in: PubMed
    Score: 0.214
  21. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
    View in: PubMed
    Score: 0.214
  22. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
    View in: PubMed
    Score: 0.214
  23. Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail. 2019 10; 21(10):1288-1291.
    View in: PubMed
    Score: 0.212
  24. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2019 08; 7(8):664-675.
    View in: PubMed
    Score: 0.212
  25. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 07; 12(7):e006125.
    View in: PubMed
    Score: 0.211
  26. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 03 26; 73(11):1264-1272.
    View in: PubMed
    Score: 0.206
  27. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019 03; 21(3):337-341.
    View in: PubMed
    Score: 0.206
  28. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. JACC Heart Fail. 2019 01; 7(1):25-32.
    View in: PubMed
    Score: 0.204
  29. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2018 11; 11(11):e005288.
    View in: PubMed
    Score: 0.202
  30. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circ Heart Fail. 2018 11; 11(11):e005312.
    View in: PubMed
    Score: 0.202
  31. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol. 2018 10 01; 3(10):1000-1005.
    View in: PubMed
    Score: 0.201
  32. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. JACC Heart Fail. 2018 08; 6(8):689-697.
    View in: PubMed
    Score: 0.197
  33. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 06 01; 3(6):498-505.
    View in: PubMed
    Score: 0.196
  34. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
    View in: PubMed
    Score: 0.194
  35. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. J Card Fail. 2018 May; 24(5):313-320.
    View in: PubMed
    Score: 0.193
  36. Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. JACC Heart Fail. 2018 08; 6(8):653-661.
    View in: PubMed
    Score: 0.193
  37. Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance. Circ Heart Fail. 2017 Dec; 10(12).
    View in: PubMed
    Score: 0.189
  38. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. Eur J Heart Fail. 2018 03; 20(3):483-490.
    View in: PubMed
    Score: 0.189
  39. Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. Eur J Heart Fail. 2018 04; 20(4):815-816.
    View in: PubMed
    Score: 0.188
  40. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail. 2017 07; 5(7):471-482.
    View in: PubMed
    Score: 0.184
  41. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. JACC Heart Fail. 2017 04; 5(4):241-252.
    View in: PubMed
    Score: 0.181
  42. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 05; 5(5):333-340.
    View in: PubMed
    Score: 0.180
  43. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 06; 68(22):2425-2436.
    View in: PubMed
    Score: 0.177
  44. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.177
  45. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016 07 19; 68(3):241-248.
    View in: PubMed
    Score: 0.172
  46. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
    View in: PubMed
    Score: 0.172
  47. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.171
  48. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.168
  49. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016 Feb 01; 37(5):455-62.
    View in: PubMed
    Score: 0.162
  50. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
    View in: PubMed
    Score: 0.158
  51. Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease. J Hypertens. 2014 Dec; 32(12):2479-86; discussion 2486-7.
    View in: PubMed
    Score: 0.154
  52. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.
    View in: PubMed
    Score: 0.151
  53. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail. 2014 Jul; 7(4):590-5.
    View in: PubMed
    Score: 0.148
  54. Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. J Hypertens. 2014 Jan; 32(1):174-80.
    View in: PubMed
    Score: 0.144
  55. Utility of lung ultrasound in predicting pulmonary and cardiac pressures. Eur J Heart Fail. 2012 Nov; 14(11):1276-84.
    View in: PubMed
    Score: 0.132
  56. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011 Dec; 162(6):966-972.e10.
    View in: PubMed
    Score: 0.124
  57. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2012 Feb; 14(2):185-92.
    View in: PubMed
    Score: 0.123
  58. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011 Sep; 29(9):1829-36.
    View in: PubMed
    Score: 0.123
  59. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011 Nov; 58(5):717-28.
    View in: PubMed
    Score: 0.122
  60. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011 May; 32(10):1227-34.
    View in: PubMed
    Score: 0.118
  61. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010 Sep; 12(9):936-42.
    View in: PubMed
    Score: 0.113
  62. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010 Feb; 55(2):241-8.
    View in: PubMed
    Score: 0.109
  63. Therapeutic approaches to diastolic dysfunction. Curr Hypertens Rep. 2009 Aug; 11(4):283-91.
    View in: PubMed
    Score: 0.106
  64. EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. Ther Adv Cardiovasc Dis. 2009 Dec; 3(6):429-39.
    View in: PubMed
    Score: 0.106
  65. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007 Nov 13; 50(20):1959-66.
    View in: PubMed
    Score: 0.094
  66. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2021 Oct 22; CIRCHEARTFAILURE120008293.
    View in: PubMed
    Score: 0.062
  67. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug; 110(8):1334-1349.
    View in: PubMed
    Score: 0.060
  68. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
    View in: PubMed
    Score: 0.060
  69. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021 May 18; 143(20):1962-1972.
    View in: PubMed
    Score: 0.060
  70. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. Eur J Heart Fail. 2021 05; 23(5):776-784.
    View in: PubMed
    Score: 0.059
  71. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex. Circ Heart Fail. 2021 03; 14(3):e007891.
    View in: PubMed
    Score: 0.059
  72. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. Am Heart J. 2021 07; 237:45-53.
    View in: PubMed
    Score: 0.059
  73. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.059
  74. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Eur J Heart Fail. 2021 04; 23(4):632-643.
    View in: PubMed
    Score: 0.059
  75. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Fail. 2021 04; 8(2):1130-1138.
    View in: PubMed
    Score: 0.059
  76. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021 01 05; 325(1):39-49.
    View in: PubMed
    Score: 0.059
  77. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug; 110(8):1234-1248.
    View in: PubMed
    Score: 0.058
  78. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2021 01; 9(1):42-51.
    View in: PubMed
    Score: 0.058
  79. Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. ESC Heart Fail. 2020 Oct 19.
    View in: PubMed
    Score: 0.058
  80. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2021 Jan 26; 143(4):298-309.
    View in: PubMed
    Score: 0.058
  81. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.
    View in: PubMed
    Score: 0.058
  82. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. J Am Heart Assoc. 2020 10 20; 9(19):e017462.
    View in: PubMed
    Score: 0.058
  83. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 12; 22(12):2370-2379.
    View in: PubMed
    Score: 0.057
  84. Associations Between Depressive Symptoms and HFpEF-Related Outcomes. JACC Heart Fail. 2020 12; 8(12):1009-1020.
    View in: PubMed
    Score: 0.057
  85. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation. 2020 10 27; 142(17):1623-1632.
    View in: PubMed
    Score: 0.057
  86. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020 07 01; 41(25):2379-2392.
    View in: PubMed
    Score: 0.057
  87. The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 11; 22(11):2123-2133.
    View in: PubMed
    Score: 0.056
  88. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 04 14; 323(14):1353-1368.
    View in: PubMed
    Score: 0.056
  89. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. 2020 04 01; 5(4):432-441.
    View in: PubMed
    Score: 0.056
  90. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.055
  91. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 03; 22(3):528-538.
    View in: PubMed
    Score: 0.055
  92. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
    View in: PubMed
    Score: 0.054
  93. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. JACC Heart Fail. 2019 12; 7(12):1022-1028.
    View in: PubMed
    Score: 0.054
  94. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 11 21; 381(21):1995-2008.
    View in: PubMed
    Score: 0.054
  95. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):601-612.
    View in: PubMed
    Score: 0.053
  96. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.
    View in: PubMed
    Score: 0.052
  97. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circ Heart Fail. 2019 03; 12(3):e005766.
    View in: PubMed
    Score: 0.052
  98. Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. JACC Heart Fail. 2019 04; 7(4):336-346.
    View in: PubMed
    Score: 0.051
  99. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. J Am Coll Cardiol. 2019 01 08; 73(1):29-40.
    View in: PubMed
    Score: 0.051
  100. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
    View in: PubMed
    Score: 0.051
  101. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019 01; 21(1):40-49.
    View in: PubMed
    Score: 0.051
  102. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.051
  103. The frailty syndrome and outcomes in the TOPCAT trial. Eur J Heart Fail. 2018 11; 20(11):1570-1577.
    View in: PubMed
    Score: 0.050
  104. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 06; 6(6):489-498.
    View in: PubMed
    Score: 0.049
  105. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018 03 07; 39(10):840-849.
    View in: PubMed
    Score: 0.048
  106. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018 03 06; 71(9):1021-1034.
    View in: PubMed
    Score: 0.048
  107. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circ Heart Fail. 2018 03; 11(3):e004457.
    View in: PubMed
    Score: 0.048
  108. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation. 2018 02 27; 137(9):961-972.
    View in: PubMed
    Score: 0.048
  109. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
    View in: PubMed
    Score: 0.048
  110. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018 03; 20(3):514-522.
    View in: PubMed
    Score: 0.047
  111. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2017 Nov 14; 70(20):2490-2500.
    View in: PubMed
    Score: 0.047
  112. Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia. 2018 03; 61(3):581-588.
    View in: PubMed
    Score: 0.047
  113. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.047
  114. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur J Heart Fail. 2018 02; 20(2):268-277.
    View in: PubMed
    Score: 0.047
  115. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.046
  116. Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. N Engl J Med. 2017 04 27; 376(17):1690-1692.
    View in: PubMed
    Score: 0.045
  117. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. Am Heart J. 2017 May; 187:145-155.
    View in: PubMed
    Score: 0.045
  118. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016 Oct; 18(10):1228-1234.
    View in: PubMed
    Score: 0.043
  119. Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). J Am Heart Assoc. 2016 04 23; 5(4).
    View in: PubMed
    Score: 0.042
  120. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21; 374(16):1521-32.
    View in: PubMed
    Score: 0.042
  121. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2016 06; 4(6):477-86.
    View in: PubMed
    Score: 0.042
  122. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail. 2016 Mar; 9(3):e001937.
    View in: PubMed
    Score: 0.042
  123. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes Endocrinol. 2016 Apr; 4(4):309-17.
    View in: PubMed
    Score: 0.042
  124. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes Metab. 2016 Feb; 18(2):169-77.
    View in: PubMed
    Score: 0.042
  125. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.041
  126. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Feb; 4(2):152-158.
    View in: PubMed
    Score: 0.041
  127. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10; 66(19):2059-2071.
    View in: PubMed
    Score: 0.041
  128. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail. 2015 Nov; 17(11):1201-7.
    View in: PubMed
    Score: 0.041
  129. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. Eur J Heart Fail. 2015 Oct; 17(10):1075-83.
    View in: PubMed
    Score: 0.041
  130. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 07; 36(38):2576-84.
    View in: PubMed
    Score: 0.040
  131. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. Eur Heart J. 2015 Sep 21; 36(36):2463-9.
    View in: PubMed
    Score: 0.040
  132. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14; 36(7):434-9.
    View in: PubMed
    Score: 0.039
  133. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015 Jan 06; 131(1):34-42.
    View in: PubMed
    Score: 0.038
  134. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 06; 131(1):54-61.
    View in: PubMed
    Score: 0.038
  135. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11):993-1004.
    View in: PubMed
    Score: 0.038
  136. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014 Jul; 16(7):817-25.
    View in: PubMed
    Score: 0.037
  137. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014 Jul; 7(4):573-9.
    View in: PubMed
    Score: 0.037
  138. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10; 370(15):1383-92.
    View in: PubMed
    Score: 0.037
  139. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail. 2013 Sep 01; 6(5):970-6.
    View in: PubMed
    Score: 0.035
  140. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep; 15(9):1062-73.
    View in: PubMed
    Score: 0.034
  141. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 Mar 28; 368(13):1210-9.
    View in: PubMed
    Score: 0.034
  142. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013 Mar; 6(2):184-92.
    View in: PubMed
    Score: 0.034
  143. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012 Dec 20; 367(25):2375-84.
    View in: PubMed
    Score: 0.033
  144. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 06; 367(23):2204-13.
    View in: PubMed
    Score: 0.033
  145. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012 Nov 13; 60(20):2082-9.
    View in: PubMed
    Score: 0.033
  146. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J. 2011 Oct; 162(4):748-755.e3.
    View in: PubMed
    Score: 0.031
  147. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2011 Dec; 12(4):483-90.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.